Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Cabaletta Bio (CABAResearch Report) today and set a price target of $21.00. The company’s shares closed last Thursday at $13.07.

According to, Livshits is a top 25 analyst with an average return of 94.2% and a 80.3% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cabaletta Bio with a $20.50 average price target.

See today’s analyst top recommended stocks >>

Cabaletta Bio’s market cap is currently $314.4M and has a P/E ratio of -3.00. The company has a Price to Book ratio of 2.64.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.

Source link